Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

被引:5
|
作者
Carr, Rebecca A. [1 ]
Hsu, Meier [2 ]
Harrington, Caitlin A. [1 ]
Tan, Kay See [2 ]
Bains, Manjit S. [1 ]
Bott, Matthew J. [1 ]
Ilson, David H. [3 ]
Isbell, James M. [1 ]
Janjigian, Yelena Y. [3 ]
Maron, Steven B. [3 ]
Park, Bernard J. [1 ]
Rusch, Valerie W. [1 ]
Sihag, Smita [1 ]
Wu, Abraham J. [4 ]
Jones, David R. [1 ]
Ku, Geoffrey Y. [3 ]
Molena, Daniela [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
CROSS regimen; esophageal adenocarcinoma; FOLFOX; induction; positron emission tomography-directed chemoradiation; COMPLETE PATHOLOGICAL RESPONSE; ESOPHAGOGASTRIC JUNCTION; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; TUMOR-REGRESSION; SURVIVAL; CHEMOTHERAPY; CANCER; CARCINOMA; THERAPY;
D O I
10.1097/SLA.0000000000005163
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC. Summary of Background Data: nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy. Methods: We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with >= 90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression. Results: In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group. Conclusions: Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.
引用
收藏
页码:E538 / E544
页数:7
相关论文
共 50 条
  • [31] FOLFOX or FOLFOX plus radiation therapy for locally advanced or metastatic esophageal squamous cell carcinoma
    Shiraishi, Kazuhiro
    ANNALS OF ONCOLOGY, 2021, 32 : S310 - S310
  • [32] CHEMORADIATION THERAPY FOLLOWED BY SURGERY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER
    Iannopollo, Mauro
    D'alessandro, Michelina
    Santi, Stefano
    Fabrini, Maria Grazia
    Lencioni, Monica
    Orlandini, Cinzia
    Cionini, Luca
    Rossi, Mauro
    Ricci, Sergio
    ANNALS OF ONCOLOGY, 2004, 15 : 71 - 72
  • [33] Utility of repeated 18F-FDG PET/CT during induction chemotherapy to identify responders in locally advanced esophageal adenocarcinoma
    Razzouk-Cadet, M.
    Francois, E.
    Mouroux, J.
    Viau, P.
    Grangeon, C.
    Maurel, F.
    Thelu, M.
    Zwarthoed, C.
    Mahamat, A.
    Darcourt, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S195 - S196
  • [34] Induction Chemotherapy for Locally Advanced Esophageal Cancer
    Harada, Guilherme
    da Cunha Colombo Bonadio, Renata Rodrigues
    Cordeiro de Araujo, Frederico Cantarino
    Victor, Carolina Ribeiro
    Aissar Sallum, Rubens Antonio
    Ribeiro Junior, Ulysses
    Cecconello, Ivan
    Takeda, Flavio Roberto
    de Castria, Tiago Biachi
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (02) : 498 - 505
  • [35] Induction Chemotherapy for Locally Advanced Esophageal Cancer
    Guilherme Harada
    Renata Rodrigues da Cunha Colombo Bonadio
    Frederico Cantarino Cordeiro de Araújo
    Carolina Ribeiro Victor
    Rubens Antonio Aissar Sallum
    Ulysses Ribeiro Junior
    Ivan Cecconello
    Flávio Roberto Takeda
    Tiago Biachi de Castria
    Journal of Gastrointestinal Cancer, 2020, 51 : 498 - 505
  • [36] Induction chemotherapy for locally advanced esophageal cancer
    Harada, G.
    Bonadio, R. R. D. C. C.
    de Araujo, F. C. C.
    Victor, C. R.
    Takeda, F. R.
    Sallum, R. A. A.
    Junior, U. R.
    Cecconello, I.
    de Castria, T. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Locally advanced rectal cancer: What is the evidence for induction chemoradiation?
    Glynne-Jones, Rob
    Harrison, Mark
    ONCOLOGIST, 2007, 12 (11): : 1309 - 1318
  • [38] Surgical Decision Making in Locally Advanced Esophageal Adenocarcinoma
    Sanderfer, Van C.
    Holland, Alexis
    Donahue, Erin
    Shea, Reilly
    Schwarzen, Ella
    Mullis, Nicholas
    Bellavia, Sophia
    Kadakia, Kunal
    Salo, Jonathan
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S77 - S77
  • [39] Clinical Predictors of Locally Advanced Pathology in Esophageal Adenocarcinoma
    Cifuentes, Juan David Gomez
    Haider, Mahnur
    Sanaka, Madhusudhan R.
    Kumar, Prabhat
    Bena, James
    McMichael, John
    Sohal, Davendra P.
    Raja, Siva
    Murthy, Sudish
    Thota, Prashanthi N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [40] Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not?
    Lu, Yueh-Feng
    Chung, Chen-Shuan
    Liu, Chao-Yu
    Shueng, Pei-Wei
    Wu, Le-Jung
    Hsu, Chen-Xiong
    Kuo, Deng-Yu
    Hou, Pei-Yu
    Chou, Hsiu-Ling
    Leong, Ka-, I
    How, Cheng-Hung
    Chou, San-Fang
    Wang, Li-Ying
    Hsieh, Chen-Hsi
    ONCOLOGIST, 2018, 23 (12): : 1426 - 1435